Pulmonology

Nerandomilast, with a PDUFA date of Q4 2025, leads the potential breakthrough therapies, with inhaled treprostinil and admilparant advancing quickly behind.

ACOG CEO: “In the face of misinformation and vaccine hesitancy, a strong, evidence-based recommendation...from a trusted clinician can go a long way."

Large US cohort study finds COVID-19 infection increases short-term risk of asthma, allergic rhinitis, and chronic rhinosinusitis, while vaccination lowers these risks.

The US FDA approved brensocatib as the first treatment for non–cystic fibrosis bronchiectasis.

Your daily dose of the clinical news you may have missed.

Apnimed's first-in-class anti-apneic AD109 increases upper airway muscle tone during sleep; the company plans to file an NDA with the FDA in early 2026.

Astegolimab did result in a statistically significant reduction of annualized exacerbation rates in a similar phase 2b trial, but the result was not replicated in phase 3.

A smartphone-based asthma management program significantly enhanced symptom control, but may require engagement or cultural tailoring to expand the effect.

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.